|
公告日期：106 年 11 月 3 日
一、 主旨：本院公開徵選「無血清細胞培養腸病毒71型疫苗」產學合作廠商。
二、 說明：
本院已完成「無血清細胞培養腸病毒71型疫苗」開發，已於台灣完成第一期臨床試驗，現徵求此疫苗之產學合作廠商。
三、 廠商資格：須具備下列條件者
1. 依法登記且無違法紀錄。
2. 具有相關技術開發經驗及能力者佳。
3. 具國際合作經驗及臨床試驗經驗者佳。
4. 願意長期投入研發資金者。
四、 實質審查
符合上述資格且有意願合作者，請填妥「產學合作企劃書」(格式如附件)，於民國106年12月3日前以郵寄正本及電子郵件方式，
送達國家衛生研究院技轉及育成中心翁于皕小姐 收（地址：「苗栗縣350竹南鎮科研路35號行政大樓3樓 技轉及育成中心」，
E-mail：rubyweng@nhri.org.tw）。本院將於企劃書收件截止後約1個月(得視實際狀況而定)通知審查結果。
附檔：
附件一：技術公告電子檔
附件二：產學合作企劃書
---------------------------------------------------------------------
1. Title: NHRI technology, “Serum-Free, Cell-Based EV-71 Vaccine Production” (abbreviated as“The Technology”) available for
industry-academia collaboration.
2. Description:
NHRI have developed EV71 vaccine using serum-free Vero cell culture system and have completed the phase I clinical study in
Taiwan.
The Technology is available for industry-academia collaboration.
3. Potential collaboration partner qualifications:
(1) be incorporated and approved by law and does not have any record of misconduct or conviction for any offense
(2) has related experience and skills for developing The Technology
(3) has experience of international collaboration and clinical trial
(4) be willing to provide long-term investment
4. Qualification review：
Potential collaboration partners meeting the above qualifications, please fill out the “Industry-Academia Collaboration Proposal”
(attachment II) and send the application through both mail (hard copy) and email to Ms. Ruby Weng before December 3, 2017
(Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town,
Miaoli County 35053, Taiwan, R.O.C.; E-mail：rubyweng@nhri.org.tw) The qualification of potential collaboration partners will
be reviewed by NHRI. Qualified potential collaboration partners will be informed by email about a month (could vary depending
on the situation) after the application deadline.
Attachments:
I: Announcement
II: Industry-Academia Collaboration Proposal
|
